|
Talizumab (TNX-901) is a humanized monoclonal antibody that was under development by Tanox in Houston, Texas as a new-concept therapeutic for allergic diseases. The unique anti-IgE antibody was designed to target immunoglobulin E (IgE) and IgE-expressing B lymphocytes specifically, without binding to IgE already bound by the high affinity IgE receptors on mast cells and basophils. Talizumab was tested in clinical trials at National Jewish Medical and Research Center and other medical centers and allergy clinics across the U. S. and shown to be able to prevent allergic reactions to accidental exposure to peanuts, which is contained in many kinds of foods. ==History== The U.S. Food and Drug Administration (FDA) "fast-tracked" TNX-901. A drug is given a fast-track status if it meets a medical need not currently being met by any medication. TNX-901 was developed by Houston-based Tanox, started by two biomedical scientists, Nancy T. Chang and Tse Wen Chang, in 1986. There was a legal dispute whether Tanox had the right to independently develop TNX-901 under the tripartite partnership formed by Tanox, Novartis, and Genentech in 1996. Trials of TNX-901 for treating extreme peanut sensitivity, which affect children especially, were unfortunately mired in legal battles.〔Pollack A. Wrangling May Delay Peanut Allergy Drug. ''New York Times'' March 13, 2003. http://www.nytimes.com/2003/03/13/business/wrangling-may-delay-peanut-allergy-drug.html?pagewanted=all&src=pm〕〔Hamilton DP. How Genentech, Novartis Stifled A Promising Drug. ''Wall Street Journal'' April 5, 2005. http://online.wsj.com/article/0,,SB111265511632497703-search,00.html〕〔(【引用サイトリンク】title=Trials of an allergy drug Remedy against peanuts is mired in legal battles - International Herald Tribune - HighBeam Research )〕 In the original collaborative agreement signed between Tanox and Ciba-Geigy in 1990 to co-develop the anti-IgE antibody program, the two companies agreed to select a top candidate for manufacturing process development and clinical trials. The agreement stipulated that Tanox could develop any “left-over” antibody candidate, but when and if Tanox sought a corporate partner to further develop and commercialize the product, Ciba-Geigy would have the right of first refusal. (Note Ciba-Geigy merged with Sandoz to form Novartis in 1996.) When Genentech joined in the anti-IgE program in 1996, the original 2-way Tanox-Ciba Geigy agreement was expanded to a tripartite agreement. A joint steering committee formed by members from the three companies chose omalizumab (trade name Xolair) developed by Genentech for further development, on the basis that it had a better developed manufacturing process than TNX-901. Tanox took a position that because the original clause concerning its right to develop a left-over candidate was not explicitly removed in the tripartite agreement, it should still have a right to do so with the recognition that its corporate partners, Novartis and Genentech, would still command right of first refusal on the product Tanox developed. Based on this position, Tanox proceeded with a phase II clinical trial of TNX-901 on peanut allergy, with the understanding that this indication was important and urgent, but was not on the top agenda of clinical testing planned by the steering committee. As the issue on Tanox’s right to develop TNX-901 was moved to the legal stage, a judge of a California court remarked that Tanox should have such a right, but then passed the case for arbitration.〔http://www.thefreelibrary.com/Court+Stays+Lawsuit+Against+Tanox,+Inc.%3B+Judge+Returns+Parties+to...-a080862592〕 The arbitration panel eventually ruled the case in favor of the giant partners, Genentech and Novartis, in 2002. The managers of Tanox agonized over the decision, in the midst of very positive results from the phase II studies of TNX-901 on peanut allergy. The media hailed the success of the trials, but expressed outcry over the fate of the TNX-901 program on peanut allergy.〔〔Delayed help for peanut allergy sufferers - A new drug has been shown to offer protection against this sometimes fatal malady. Further testing, however, is stuck in a legal limbo. ''Business Week'' March 10, 2003. http://www.businessweek.com/technology/content/mar2003/tc20030310_8777_tc024.htm〕〔Robbins-Roth C. A David Vs. Goliath Biotech Story, With Goliath Winning. ''BioWorld Today'' April 8, 2005. http://www.bioventureconsultants.com/4-8-05_Article.html〕 Ten years have passed, since Tanox was forced to put its TNX-901 program on the shelf. In the meantime, a phase II clinical trial of omalizumab on peanut allergy failed to finish, as a couple of patients suffered anaphylactic reactions during the testing for baseline sensitivity for peanut allergens and the trial had to be suspended. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Talizumab」の詳細全文を読む スポンサード リンク
|